Chapter 13  JURISDICTION AND PROCEDURE  1

Introduction  3

§13.01 U.S. District Courts  3

[A] Subject Matter Jurisdiction over Patent Cases  3


[2] "Arising Under" Jurisdiction  4

[a] "Creation" Test  5

[b] "Serious Federal Interest" Test  6

[i] Christianson (U.S. 1988)  6

[ii] Gunn (U.S. 2013)  7


[B] Personal Jurisdiction  13


[2] Specific Personal Jurisdiction  14

[a] Stream-of-Commerce Theory  15

[b] Sending Enforcement Letters  18

[C] Venue  23


[5] Suing Where Accused Infringer Has "Committed Acts of Infringement" and Has a "Regular and Established Place of Business"  31

[a] In re Cordis (Fed. Cir. 1985)  31

[b] Representative Post-TC Heartland (U.S. 2017) District Court Decisions  35


[i] Cray (2017)  38

[ii] ZTE (2018)  44

[d] Waiver or Forfeiture of Improper Venue Defense  44

[6] Venue for Infringement Actions Against Foreign Corporations  49


[a] Correction of Inventorship  52

[b] Declaratory Judgment Actions  52
### §13.02 U.S. International Trade Commission

### §13.03 U.S. Court of Appeals for the Federal Circuit

- **[A]** Subject Matter-Specific Appellate Jurisdiction
- **[B]** Critiques of the Federal Circuit
- **[C]** Standards of Review
  - **[1]** Appeals from Federal District Courts
    - **[a]** Jury Trial
    - **[b]** Bench Trial
  - **[2]** Appeals from the International Trade Commission
  - **[3]** Appeals from the U.S. Patent and Trademark Office

### §13.04 U.S. Supreme Court

- **[A]** Before Formation of the Federal Circuit
- **[B]** After Formation of the Federal Circuit

### §13.05 Standing to Sue for Patent Infringement

- **[A]** Introduction
- **[B]** Licensees
- **[C]** Declaratory Judgment Plaintiffs
- **[D]** Appeals to Federal Circuit from USPTO

### §13.06 Patent Declaratory Judgment Actions

- **[A]** Introduction
- **[B]** Pre- *MedImmune* “Reasonable Apprehension” Test
- **[C]** *MedImmune v. Genentech* (U.S. 2007)
- **[D]** Post- *MedImmune* Federal Circuit Decisions
  - **[1]** “All the Circumstances” Test
  - **[2]** Decisions Illustrating *Lack* of Declaratory Judgment Jurisdiction
  - **[3]** Decisions Illustrating *Existence* of Declaratory Judgment Jurisdiction
  - **[4]** Covenants Not to Sue
- **[E]** Burden of Proof

### Chapter 14 ANALYTICAL FRAMEWORK FOR PATENT INFRINGEMENT

- **§14.01** Statutory Basis: 35 U.S.C. §271
- **§14.02** Direct Versus Indirect Infringement
  - **[A]** Introduction

---

Last revised 23 January 2021
[B] Direct Infringement Under §271(a) 139
  [1] Making 139
  [2] Using 143
    [a] Generally 143
    [b] Using a Claimed System 146
    [c] Using a Claimed Method 154
  [3] Selling 156
  [4] Offering to Sell 158
  [5] Importing 162

§14.03 Territoriality Aspects of §271(a) 164
  [A] Introduction 164
  [B] Use of Processes or Methods Within the United States 165
  [C] “Beneficial Use” Doctrine 166
  [D] “Sells” Within the United States 170
  [E] “Offer[s] to Sell” Within the United States 175

§14.04 Temporal Aspects of §271 179
  [A] Pre-Issuance Acts 179
  [B] Post-Issuance Acts 180

§14.05 Divided Direct Infringement by Multiple Entities 181
  [A] Introduction 181
  [B] Akamai II (Fed. Cir. 2012) (en banc) 184
  [C] Akamai III (U.S. 2014) 188
  [D] Akamai V (Fed. Cir. 2015) (en banc) 190
    [1] “Directs or Controls” Liability 192
      [a] Service Provider-Customer Relationship 193
      [b] Physician-Patient Relationship 194
      [c] “Partnership-Like” Relationship 197
    [3] Subsequent History 202
  [E] Pleading Joint (or “Divided”) Direct Infringement 202
    [1] Illustrative Cases Not Alleging Sufficient Facts for a “Plausible” Claim 202
    [2] Illustrative Cases That Do Alleged Sufficient Facts for a “Plausible” Claim 206

§14.06 Indirect Infringement Under §271(b)–(c): Overview 211
  [A] Practicing Less Than Complete Claimed Invention 211
  [B] Intent Required 211
  [C] Historical Background 212
  [D] Direct Infringement as Predicate to Indirect Liability 214

§14.07 Two-Step Analysis for Patent Infringement 215

Chapter 15 PATENT CLAIM INTERPRETATION 217

§15.01 The Central Role of Patent Claims 218
§15.02 Judge Versus Jury as Interpreter 221
  [A] Pre-Markman 221

Last revised 23 January 2021
Markman Hearings 224

Must a District Court Always Expressly Interpret Claim Terms? 226

Evidentiary Hierarchy for Claim Interpretation 234

[A] Intrinsic Evidence 235
[B] Extrinsic Evidence 235
[C] "Contextualist" Versus "Literalist" Approaches 237
[D] The En Banc Phillips Decision (Fed. Cir. 2005) 239

Canons of Patent Claim Interpretation 241

[A] Perspective: Person Having Ordinary Skill in the Art 242
[C] Self-Defined Terms ("Own Lexicographer" Rule) 254
[1] Express Redefinition 254
[2] Implicit Redefinition 255
[D] Interpret Claims in View of the Written Description but Do Not Import a Limitation from the Written Description into the Claims 259
[E] Generally Do Not Exclude Preferred Embodiment 260
[F] Claim Differentiation Principle 262
[1] Definition 262
[G] Generally Do Not Interpret Claims to Preserve Validity 265
[H] The Indefinite Article "A" Generally Means One or More 267
[I] Timing: Interpret Claim Term Meaning as of Effective Filing Date 269

Disclaimer or Disavowal 277

[A] In the Specification 277
[B] During Prosecution in the USPTO 281
[1] Foundational Case 282
[2] Disavowal of Scope Must Be Clear and Unmistakable 284

Interpreting Preamble Language 292

[A] Preamble Not Scope-Limiting 292
[B] Preamble Is Scope-Limiting 295

Federal Circuit Review of Claim Interpretation Decisions 297

[A] Question of Law, Fact, or Mixed 297
[C] Criticism of De Novo Standard of Review 300
[F] Federal Circuit’s Application of Teva 316
[1] Limited Impact to Date 316
[2] Federal Circuit Must Not Consider Extrinsic Evidence in First Instance 318
[G] Interlocutory Appeals Rejected 324

Collateral Estoppel Effect of Prior Claim Interpretation Decisions 325

[A] Generally 325
Chapter 16  COMPARING THE PROPERLY INTERPRETED CLAIMS TO THE ACCUSED DEVICE  351

§16.01  Introduction  353

§16.02  Literal Infringement  353

§16.03  Infringement Under the Doctrine of Equivalents  355

[A] Historical Background and Policy Underpinnings  355

[B] Tension with the Notice Function of Claims  356

[C] All-Limitations Rule  357

[1]  Defining a “Limitation”  357


[D] The Fact Question of Equivalence  360

[1]  Function/Way/Result Test  360

[a]  Generally  360

[b]  Adequate Expert Testimony  361

[c]  Inadequate Expert Testimony  363

[d]  Determination of “Function” Not Limited to Intrinsic Evidence  366

[2]  Insubstantial Differences Test  368

[3]  Obviousness as a Test of Equivalency?  369


[E] After-Arising Technology  374

§16.04  Reverse Doctrine of Equivalents  378

§16.05  Legal Limitations on the Doctrine of Equivalents  380

[A] Overview  380

[B] Prosecution History Estoppel  383

[1]  Definition  383

[2]  Scope of Estoppel  385


[b]  Supreme Court’s Presumptive Bar Rule of Festo II (2002)  391


[a]  Mere Tangentialness  396

[b]  Unforeseeability  404
“Some Other Reason” 411

What Qualifies as a Narrowing Amendment 415
[a] Generally 415
[b] Merely “Clarifying” 415
c] Making Explicit an Inherent Characteristic 417
d] Contract Overall Scope of Claim 417

Argument-Based Estoppel 418

Prior Art 422
[1] Generally 422
[a] Generally 425
[b] Illustrative Cases 428
c] Scope of Hypothetical Claim 432
[i] Does Not Encompass All Possible Equivalents 432
[ii] Cannot Add Any Narrowing Limitations 434

Dedication to the Public 440
[1] Disclosing Without Claiming 440
[2] Level of Specificity to Work a Dedication 441

Vitiation of Claim Limitations 445
[4] Question of Law or Fact? 454

§16.06 Infringement of Means-Plus-Function Claim Elements 455
[A] Literal Infringement 456
[B] Infringement Under the Judicially-Created Doctrine of Equivalents 456

Chapter 17 INDIRECT INFRINGEMENT 459

§17.01 Introduction 460
§17.02 Inducing Infringement Under §271(b) 461
[A] Acts 463
[1] Sale of Product Needed to Infringe 463
[2] Provide Instructions, Directions, or Guidance 464
[3] Corporate Officer Liability 464
[B] Relationship Between Inducing and Direct Infringement 466
[1] Generally 466
[2] Proving Direct Infringement 467
[C] Intent Standard for Inducing Infringement 472
[a] Knowledge of the Patent Requirement; Rejected “Deliberate Disregard” Standard 473
[b] Good Faith Belief of Invalidity 475
[i] Commil I (Fed. Cir. 2013) 475
§17.03 Contributory Infringement Under §271(c) 499
[1] Supply Component 502
[2] Supply Material or Apparatus 504
[3] Repair Versus Reconstruction 505
[B] Non-Staple Article or Commodity of Commerce 506
[C] Intent Standard for Contributory Infringement 509
[D] Pleading Contributory Infringement 511
[E] Relationship to Patent Misuse 513

Chapter 18 SPECIALIZED CATEGORIES OF INFRINGEMENT 515

Introduction 516
§18.01 Drug Marketing Application Filings Under 35 U.S.C. §271(e) 516
[A] Introduction 516
[B] Technical Infringement Under §271(e)(2) 516
[1] Paragraph IV Certifications 518
[C] Safe Harbor Under §271(e)(1) 519
[D] Settlements of Hatch-Waxman Litigation 526

§18.02 Component Exports Under 35 U.S.C. §271(f) 535
[A] Deepsouth Packing v. Laitram (U.S. 1972) and Legislative Response 536
[B] “Supplying or Causing to Be Supplied” 538
[C] “Components” 538
[D] “Actively Induce the Combination” Under §271(f)(1) 544
[1] Facts of Promega v. Life Techs 545
[2] Supreme Court Reverses: “Substantial Portion” Must Be Evaluated Quantitatively 551
Chapter 19  DEFENSES TO PATENT INFRINGEMENT  569

§19.01  Introduction  571
§19.02  Noninfringement  573
§19.03  Absence of Liability for Infringement  573

[A] License  574
[1] Express License  575
[2] Implied License  576

[B] Prior User Rights  582
[1] Pre-America Invents Act of 2011  582

[C] Experimental/Research Use  585


[E] Laches and Equitable Estoppel in Initiating Patent Infringement Litigation  590
[1] Introduction  590
[a] Aukerman (Fed. Cir. 1992) (en banc)  592
[b] Petrella (U.S. 2014)  594
[c] SCA Hygiene I (Fed. Cir. 2014)  595
[d] SCA Hygiene II (Fed. Cir. 2015) (en banc)  597
[e] Supreme Court Eviscerates Patent Laches Defense in SCA Hygiene III (U.S. 2017)  600

[2] Laches Framework  604
[a] Elements  604
[i] Unreasonable Delay by Patentee  605
[ii] Material Prejudice to Accused Infringer  608
[b] “Should Have Known”  609

[a] Introduction  610
[b] Elements  611
[c] Privity  613
[d] Misleading Communication  614
[e] Reasonable Reliance  615
[f] Relationship Between Patent Claims, Misleading Conduct, and Reliance Thereon  615

[F] State Sovereign Immunity  621
[G] Temporary Presence Exemption  624
[H] Patent Exhaustion  626
[1] Generally  626
Unconditional Sale of Patented Product 627
Conditioned Sale of Patented Product 629
   [a] Federal Circuit Position 629
      [i] Mallinckrodt (Fed. Cir. 1992) 629
      [ii] Lexmark Int'l (Fed. Cir. 2016) (en banc) 631
   [b] Supreme Court Reversal: Impression Prods., Inc. v. Lexmark Int'l (2017) 634
Application to Method Claims: Quanta (U.S. 2008) 640
Self-Replicating Technology 643
   [i] Lack of Standing to Sue 645
§19.04 Unenforceability 647
   [A] Introduction 647
   [B] Inequitable Conduct 649
      [1] Acts or Omissions 650
         [a] Materiality Standards Pre-Therasense (Fed. Cir. 2011) (en banc) 656
         [b] Materiality Standard Post-Therasense (Fed. Cir. 2011) (en banc) 659
            [i] “But For” Test 661
               [a] No Allowance if USPTO Had Been Aware of Undisclosed Information 661
               [b] Nondisclosure of Inconsistent Statements or Positions 663
               [c] Nondisclosure of Prior Art 664
               [d] Nondisclosure of Corroborating Evidence 669
            [ii] “Affirmative Egregious Misconduct” Exception 672
            [iii] Cumulative Information 676
      [3] Intent to Deceive 676
         [a] Generally 676
         [b] Inferring Intent 677
            [i] Generally 677
               [ii] Adverse Inference of Intent to Deceive USPTO as Sanction for Litigation Misconduct 678
               [c] Clear and Convincing Evidence Lacking 683
               [d] Clear and Convincing Evidence Present 687
               [e] “Gross Negligence” Insufficient 690
               [f] Knowledge of Materiality Alone Insufficient 691
               [g] Intentionally Selective or Partial Withholding 693
               [h] Unreasonable Explanation for Withholding 696
      [4] Independence of Materiality and Intent Inquiries 697
      [5] Overall Equitable Balancing 698
      [7] Pleading Inequitable Conduct with Particularity 701
      [8] Curing Inequitable Conduct 705
         [a] Federal Circuit Decisions 705
      [9] Impact on Related Patents 708
         [C] Patent Misuse 710
[1] Generally 710
[2] Historical Development 712
    [a] Tying 712
    [b] Post-Patent Expiration Royalties 714
[D] Prosecution History Laches 729
[E] Unclean Hands Based on Misconduct Independent of Inequitable Conduct in Patent Procurement 732
§19.05 Invalidity 738
[A] Burden of Proof 738
    [1] Generally 738
[B] Collateral Estoppel Effect of Invalidity Adjudication 742
[C] Statutory Grounds for Invalidity 743
[D] Limits on Accused Infringer’s Standing to Assert Invalidity 744
    [1] Licensee Repudiation 744
§19.06 Antitrust Counterclaims in Patent Cases 750
[A] Generally 750
[B] Market Power 751
[C] Anticompetitive Conduct 755
    [1] Walker Process Fraud 756
    [3] Refusals to Deal 761
Chapter 20 REMEDIES FOR PATENT INFRINGEMENTEN 765
§20.01 Introduction 768
§20.02 Injunctions 769
[B] Permanent Injunctions 771
    [1] Generally 771
        [a] Generally 775
        [b] Causal Nexus Requirement 782
            [i] Apple III (Fed. Cir. 2013) 783
            [ii] Apple IV (Fed. Cir. 2015) 787
        [c] Standard Essential Patents/FRAND Licensing 794
§20.05 Enhanced Damages and Willful Infringement 879

[B] Enhancement Based on Willfulness 879
[1] Generally 879
[C] Willfulness Pre-Seagate (2007) 885
[1] Duty of Due Care 885
[2] Adverse Inference 885
[D] The Seagate Standard: Objective Recklessness 888
[1] Objective Recklessness 888
[2] Seagate’s Two-Part Standard for Willfulness 889
[a] Objective Recklessness Prong: High Likelihood of Infringement 890
[b] Subjective Prong: Infringer Knew or Should Have Known of Risk 892
[3] Scope of Waiver 893
[E] Judge Versus Jury and Standard of Review 893
[1] Jury Question 893
[a] Bard Peripheral (Fed. Cir. 2012) 894
[b] Halo (U.S. 2016) 895
[F] America Invents Act of 2011 Codification 897
[G] Supreme Court Rewrites Law of Willfulness (Halo 2016) 899
[a] WBIP v. Kohler (Fed. Cir. 2016) 913
[b] Halo v. Pulse (Fed. Cir. 2016) 915
[c] Stryker v. Zimmer (Fed. Cir. 2016) 916
[d] Arctic Cat v. Bombardier (Fed. Cir. 2017) 918

§20.06 Attorney Fees in Exceptional Cases 920
[B] Discretionary with District Court 922
[C] Categories of “Exceptional” Cases 924
[1] Attorney Fees Imposed Against Patentees: Octane Fitness 928
[a] Octane Fitness I (Fed. Cir. 2012) 929
[b] Octane Fitness II (U.S. 2014) 931
[2] Attorney Fees Imposed Against Infringers 934
[D] Burden of Proof 955
[E] Standard of Review 956
§20.07 Rule 11 Sanctions 972
§20.08 Prejudgment Interest 976
§20.09 Costs 978
§20.10 Patent Marking 980
[B] Notice 981
[C] Marking Patented Articles Versus Methods 983
[D] “Patent Pending” Designations 983
[E] False Marking 984
[F] Burdens of Proof and Production When Patentee Assertedly Failed to Mark 986
§20.11 Provisional Compensation Remedy 988
[B] “Substantially Identical” Inventions 988
[C] Actual Notice 989
[D] Statute of Limitations 991
[E] Decisions 991
§20.12 Time Limitation on Damages Recovery 992
[B] Six Year Pre-Filing Period 993
[C] Claims Against the U.S. Government 993

Chapter 21 CORRECTING PATENTS IN THE USPTO (REISSUE AND REEXAMINATION) 995

§21.01 Introduction 996
§21.02 Certificates of Correction 996
[A] USPTO at Fault 997
[B] Applicant at Fault 998
[C] No Change in Claim Scope Permitted 998
[D] Effect of Certificate 998
§21.03 Reissue 999
[A] Overview 999
[B] Historical Development 1000
[1] “Inoperative or Invalid” 1002
[3] New Matter Prohibition 1003
[D] Broadening Reissues 1012
[1] Two-Year Time Bar 1012
Chapter 22  CHALLENGING PATENTS IN THE USPTO (AIA-IMPLEMENTED PROCEDURES)  1051

§22.01  Introduction  1053

§22.02  Inter Partes Review  1055

[A] Introduction  1055

[1] 2012 Implementation  1055

[2] Statistical Information  1056


[B] Scope  1059

[C] Institution  1060


[2] Claim Interpretation for Institution Decision  1061

[3] Non-Appealability of Institution Decision  1063

[a] Statutory Basis  1063

[b] In re Cuozzo (Fed. Cir. 2015)  1064

[c] Cuozzo v. Lee (U.S. 2016)  1066

[d] Post-Cuozzo Federal Circuit Decisions on Non-Appealability of PTAB Institution Determinations  1071

[i] Are §315 Time Bar Determinations Appealable to Federal Circuit?  1072

Last revised 23 January 2021
[D] Estoppel Effect

[D] Estoppel Effect

[E] Timing Issues

[1] Time Bars to Filing an IPR in the USPTO


[b] Prior Infringement Action by Patentee Against IPR Petitioner, Its Privy, or Real Party in Interest [35 U.S.C. §315(b)]

[j] Judicial Non-Reviewability of PTAB §315(b) Time-Bar Determinations

[a] Achates (Fed. Cir. 2015)

[b] Wi-Fi One I (Fed. Cir. 2016)

[c] Wi-Fi One II (Fed. Cir. 2018) (en banc)

[d] Thryv (U.S. 2020)


[2] Stays of Parallel District Court Litigation When IPRs Have Been Filed

[a] Automatic Stay

[b] Discretionary Stay

[F] Broadest Reasonable Construction Rule for IPRs

[1] Propriety of BRC

[a] Generally

[b] In re Cuozzo (Fed. Cir. 2015)

[c] Cuozzo v. Lee (U.S. 2016)

[2] Limits on BRC


[G] Motions to Amend Claims

[1] Legal Framework

[2] Prior Art Not Relied on to Institute

[3] Prior Art in Original Prosecution


[a] Introduction

[b] Aqua Prods. (Fed. Cir. 2016) (Vacated Panel Decision)

[c] Grant of Rehearing En Banc in Aqua Prods.


[i] Opinion of Judge O’Malley

[ii] Opinion of Judge Taranto

[iii] Opinion of Judge Reyna

[iv] Opinion of Judge Moore

[v] Opinion of Judge Hughes

[e] Post-Aqua Products Federal Circuit Decisions


[H] Burdens of Proof

[1] Generally

Last revised 23 January 2021
Institution Decision Does Not Shift Burdens

Constitutionality

Federal Circuit View

Supreme Court Sustains Constitutionality of IPR in *Oil States v. Greene’s Energy* (2018)

Board Must Institute or Not Institute Review of All Patent Claims Challenged in IPR Petition (*SAS Institute* (U.S. 2018))

Federal Circuit View: Partial Institution Permitted

Supreme Court View: Partial Institution Not Permitted

No Tribal Sovereign Immunity in *Inter Partes* Review

Post-Grant Review

Introduction

Effective Date

Nine-Month Window

Scope

Standard to Grant Review

Automatic Stay and Estoppel Effect

Transitional Program for Covered Business Method Patents

Introduction

Generally

Federal Circuit’s Interpretation of “Covered Business Method Patent”

USPTO First TPCBM Final Decision

Discretionary Stay

Introduction

Requirements for Design Patentability

Primarily Ornamental

Novelty

Nonobviousness

Designer of Ordinary Skill Perspective

Two-Step Analysis for Combining Design Prior Art

Secondary Considerations

Enforcement of Design Patents

“Ordinary Observer” Test of *Gorham v. White* (U.S. 1871)

Discarded “Point of Novelty” Component

Modern Standard: *Egyptian Goddess* (Fed. Cir. 2008) (*en banc*)

Illustrative Decisions After *Egyptian Goddess*

Doctrine of Equivalents and Prosecution History Estoppel

Remedies for Infringement of Design Patents

Statutory Basis: 35 U.S.C. §289


Requirement to Elect §284 or §289
### Chapter 24  PLANT PATENTS  1255

<table>
<thead>
<tr>
<th>§24.01 Introduction</th>
<th>1255</th>
</tr>
</thead>
<tbody>
<tr>
<td>§24.02 Historical Development</td>
<td>1256</td>
</tr>
<tr>
<td>[B] 1954 Amendments</td>
<td>1259</td>
</tr>
<tr>
<td>[C] Plant Variety Protection Act of 1970</td>
<td>1260</td>
</tr>
<tr>
<td>§24.03 Requirements for Plant Patent Protection</td>
<td>1262</td>
</tr>
<tr>
<td>[A] Governing Statutes</td>
<td>1262</td>
</tr>
<tr>
<td>[B] Asexual Reproduction</td>
<td>1264</td>
</tr>
<tr>
<td>[C] Variety</td>
<td>1265</td>
</tr>
<tr>
<td>[D] Distinct and New</td>
<td>1266</td>
</tr>
<tr>
<td>[E] Cultivated</td>
<td>1269</td>
</tr>
<tr>
<td>[F] Nonobvious</td>
<td>1272</td>
</tr>
<tr>
<td>§24.04 Enforcement of Plant Patents</td>
<td>1273</td>
</tr>
<tr>
<td>§24.05 Utility Patent Protection for Plants</td>
<td>1277</td>
</tr>
</tbody>
</table>

### Chapter 25  INTERNATIONAL PATENTING ISSUES  1279

<table>
<thead>
<tr>
<th>§25.01 Introduction</th>
<th>1280</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] Territorial Scope of Patents</td>
<td>1280</td>
</tr>
<tr>
<td>[B] Obtaining Foreign Patent Protection Prior to the Paris Convention</td>
<td>1281</td>
</tr>
<tr>
<td>§25.02 The Paris Convention</td>
<td>1285</td>
</tr>
<tr>
<td>[A] Introduction</td>
<td>1285</td>
</tr>
<tr>
<td>[B] National Treatment</td>
<td>1286</td>
</tr>
<tr>
<td>[C] Right of Priority</td>
<td>1287</td>
</tr>
<tr>
<td>[E] The Hilmer Rule (Pre-America Invents Act of 2011)</td>
<td>1292</td>
</tr>
<tr>
<td>[F] Limitations of the Paris Convention</td>
<td>1295</td>
</tr>
<tr>
<td>§25.03 The Patent Cooperation Treaty</td>
<td>1295</td>
</tr>
<tr>
<td>[A] Introduction</td>
<td>1295</td>
</tr>
<tr>
<td>[B] International Application Processing</td>
<td>1296</td>
</tr>
<tr>
<td>[C] National Phase</td>
<td>1297</td>
</tr>
<tr>
<td>§25.04 The World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)</td>
<td>1298</td>
</tr>
<tr>
<td>[A] Introduction</td>
<td>1298</td>
</tr>
<tr>
<td>[B] Dispute Settlement Procedures</td>
<td>1299</td>
</tr>
<tr>
<td>[C] Substantive Minimum Levels of Protection</td>
<td>1300</td>
</tr>
<tr>
<td>[D] Limitations on Compulsory Licensing</td>
<td>1301</td>
</tr>
<tr>
<td>§25.05 Patent Harmonization Issues</td>
<td>1303</td>
</tr>
<tr>
<td>[A] Procedural Harmonization</td>
<td>1303</td>
</tr>
<tr>
<td>[B] Substantive Harmonization</td>
<td>1304</td>
</tr>
<tr>
<td>[1]  First-to-File Versus First-to-Invent</td>
<td>1304</td>
</tr>
</tbody>
</table>
§25.06 Industrial Applicability Requirement of Foreign Patent Systems

[A] Definition of Industrial Applicability

[B] Morality/Public Policy Component

§25.07 Gray Market Patented Goods

[A] Domestic Exhaustion

[B] Regional (European Community-Wide) Exhaustion

[C] International Exhaustion

[1] Generally


§25.08 Enforcement of Foreign Patents in U.S. Courts

§25.09 Patent Protection in Europe

[A] Routes to Obtain Patent Protection

[B] Routes to Enforce Patents

[1] Unitary Patent System


Glossary

Table of Cases

Table of Authorities

Table of Statutes

Index